{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T23:38:34Z","timestamp":1789688314536,"version":"4.0.1"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2024,8,31]],"date-time":"2024-08-31T00:00:00Z","timestamp":1725062400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,8,31]],"date-time":"2024-08-31T00:00:00Z","timestamp":1725062400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"GSK"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1007\/s12325-024-02967-x","type":"journal-article","created":{"date-parts":[[2024,8,31]],"date-time":"2024-08-31T02:02:01Z","timestamp":1725069721000},"page":"4008-4031","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Real-World Effectiveness of Mepolizumab in Severe Asthma: Results from the Multi-country, Self-controlled Nucala Effectiveness Study (NEST)"],"prefix":"10.1007","volume":"41","author":[{"given":"Riyad Omar","family":"Al-Lehebi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mona","family":"Al Ahmad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Venkata Nagarjuna","family":"Maturu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandra Galeano","family":"Mesa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bassam","family":"Mahboub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Garcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Fernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Soares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriela","family":"Abreu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debora","family":"dos Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliana","family":"Queiroz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro","family":"Raimondi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Laucho-Contreras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saeed","family":"Noibi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gur","family":"Levy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7884-0830","authenticated-orcid":false,"given":"Sevim","family":"Bavbek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,31]]},"reference":[{"issue":"4","key":"2967_CR1","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1016\/j.chest.2019.10.053","volume":"157","author":"E Wang","year":"2020","unstructured":"Wang E, Wechsler ME, Tran TN, et al. Characterization of severe asthma worldwide: Data from the international severe asthma registry. Chest. 2020;157(4):790\u2013804.","journal-title":"Chest"},{"key":"2967_CR2","unstructured":"Global Initiative for Asthma (GINA). 2023 gina report, global strategy for asthma management and prevention. https:\/\/ginasthma.org\/2023-gina-main-report\/. Accessed 1 Mar 2024."},{"issue":"3","key":"2967_CR3","doi-asserted-by":"publisher","DOI":"10.36416\/1806-3756\/e20210367","volume":"48","author":"R Athanazio","year":"2022","unstructured":"Athanazio R, Stelmach R, Antila M, et al. Prevalence of the eosinophilic phenotype among severe asthma patients in Brazil: the BRAEOS study. J Bras Pneumol. 2022;48(3): e20210367.","journal-title":"J Bras Pneumol"},{"key":"2967_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2024.107674","volume":"228","author":"M Al-Ahmad","year":"2024","unstructured":"Al-Ahmad M, Al Zaabi A, Madkour A, et al. Expert consensus on oral corticosteroids stewardship for the treatment of severe asthma in the Middle East and Africa. Respir Med. 2024;228: 107674.","journal-title":"Respir Med"},{"issue":"3","key":"2967_CR5","doi-asserted-by":"publisher","first-page":"2103179","DOI":"10.1183\/13993003.03179-2021","volume":"60","author":"K Mortimer","year":"2022","unstructured":"Mortimer K, Reddel HK, Pitrez PM, Bateman ED. Asthma management in low and middle income countries: case for change. Eur Respir J. 2022;60(3):2103179.","journal-title":"Eur Respir J"},{"issue":"2","key":"2967_CR6","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1136\/thoraxjnl-2017-210531","volume":"73","author":"M Kerkhof","year":"2018","unstructured":"Kerkhof M, Tran TN, Soriano JB, et al. Healthcare resource use and costs of severe, uncontrolled eosinophilic asthma in the UK general population. Thorax. 2018;73(2):116\u201324.","journal-title":"Thorax"},{"issue":"8","key":"2967_CR7","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2021-060160","volume":"12","author":"N Roche","year":"2022","unstructured":"Roche N, Garcia G, de Larrard A, et al. Real-life impact of uncontrolled severe asthma on mortality and healthcare use in adolescents and adults: findings from the retrospective, observational resonance study in France. BMJ Open. 2022;12(8): e060160.","journal-title":"BMJ Open"},{"issue":"2","key":"2967_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.waojou.2020.100502","volume":"14","author":"M Caminati","year":"2021","unstructured":"Caminati M, Morais-Almeida M, Bleecker E, et al. Biologics and global burden of asthma: a worldwide portrait and a call for action. World Allergy Organ J. 2021;14(2): 100502.","journal-title":"World Allergy Organ J"},{"issue":"10277","key":"2967_CR9","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1016\/S0140-6736(21)00458-X","volume":"397","author":"J Meghji","year":"2021","unstructured":"Meghji J, Mortimer K, Agusti A, et al. Improving lung health in low-income and middle-income countries: from challenges to solutions. Lancet. 2021;397(10277):928\u201340.","journal-title":"Lancet"},{"issue":"5","key":"2967_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.waojou.2022.100647","volume":"15","author":"M Al-Ahmad","year":"2022","unstructured":"Al-Ahmad M, Mobayed H, Al Busaidi N, et al. Severe asthma treatment patterns: a multicenter observational study in the Gulf region. World Allergy Organ J. 2022;15(5): 100647.","journal-title":"World Allergy Organ J"},{"key":"2967_CR11","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s40733-017-0032-3","volume":"3","author":"D Sol\u00e9","year":"2017","unstructured":"Sol\u00e9 D, Aranda CS, Wandalsen GF. Asthma: Epidemiology of disease control in Latin America\u2014short review. Asthma Res Pract. 2017;3:4.","journal-title":"Asthma Res Pract"},{"issue":"3","key":"2967_CR12","doi-asserted-by":"publisher","DOI":"10.1002\/clt2.12232","volume":"13","author":"PJ Cooper","year":"2023","unstructured":"Cooper PJ, Figueiredo CA, Rodriguez A, et al. Understanding and controlling asthma in Latin America: a review of recent research informed by the scaala programme. Clin Transl Allergy. 2023;13(3): e12232.","journal-title":"Clin Transl Allergy"},{"key":"2967_CR13","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.rmed.2018.03.030","volume":"139","author":"D Mungan","year":"2018","unstructured":"Mungan D, Aydin O, Mahboub B, et al. Burden of disease associated with asthma among the adult general population of five Middle Eastern countries: results of the SNAPSHOT program. Respir Med. 2018;139:55\u201364.","journal-title":"Respir Med"},{"issue":"1","key":"2967_CR14","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.rmed.2011.08.013","volume":"106","author":"RM de Carvalho-Pinto","year":"2012","unstructured":"de Carvalho-Pinto RM, Cukier A, Angelini L, et al. Clinical characteristics and possible phenotypes of an adult severe asthma population. Respir Med. 2012;106(1):47\u201356.","journal-title":"Respir Med"},{"issue":"1","key":"2967_CR15","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1186\/s12890-019-0871-1","volume":"19","author":"H Neffen","year":"2019","unstructured":"Neffen H, Moraes F, Viana K, et al. Asthma severity in four countries of Latin America. BMC Pulm Med. 2019;19(1):123.","journal-title":"BMC Pulm Med"},{"key":"2967_CR16","doi-asserted-by":"publisher","first-page":"S361","DOI":"10.1016\/j.jval.2020.04.1388","volume":"23","author":"NJ Alvis-Zakzuk","year":"2020","unstructured":"Alvis-Zakzuk NJ, Carrasquilla Sotomayor M, Zakzuk Sierra J, et al. Prs69 direct medical costs of severe asthma in two Colombian reference centers. Value Health. 2020;23:S361.","journal-title":"Value Health"},{"issue":"4","key":"2967_CR17","doi-asserted-by":"publisher","first-page":"281","DOI":"10.4103\/lungindia.lungindia_220_18","volume":"35","author":"PA Koul","year":"2018","unstructured":"Koul PA, Dhar R. Economic burden of asthma in India. Lung India. 2018;35(4):281\u20133.","journal-title":"Lung India"},{"key":"2967_CR18","doi-asserted-by":"crossref","unstructured":"Mortimer K, Reddel HK, Pitrez PM, Bateman ED. Asthma management in low and middle income countries: case for change. Eur Respir J. 2022;60(3):2103179.","DOI":"10.1183\/13993003.03179-2021"},{"issue":"10","key":"2967_CR19","doi-asserted-by":"publisher","first-page":"e1423","DOI":"10.1016\/S2214-109X(22)00330-8","volume":"10","author":"M Stolbrink","year":"2022","unstructured":"Stolbrink M, Thomson H, Hadfield RM, et al. The availability, cost, and affordability of essential medicines for asthma and copd in low-income and middle-income countries: a systematic review. Lancet Glob Health. 2022;10(10):e1423\u201342.","journal-title":"Lancet Glob Health"},{"issue":"2","key":"2967_CR20","doi-asserted-by":"publisher","first-page":"71","DOI":"10.4103\/atm.atm_469_21","volume":"17","author":"MO Zeitouni","year":"2022","unstructured":"Zeitouni MO, Al-Moamary MS, Coussa ML, et al. Challenges and recommendations for the management of asthma in the Middle East and Africa. Ann Thorac Med. 2022;17(2):71\u201380.","journal-title":"Ann Thorac Med"},{"issue":"4","key":"2967_CR21","doi-asserted-by":"publisher","first-page":"1800703","DOI":"10.1183\/13993003.00703-2018","volume":"52","author":"T Volmer","year":"2018","unstructured":"Volmer T, Effenberger T, Trautner C, Buhl R. Consequences of long-term oral corticosteroid therapy and its side-effects in severe asthma in adults: a focused review of the impact data in the literature. Eur Respir J. 2018;52(4):1800703.","journal-title":"Eur Respir J"},{"issue":"7","key":"2967_CR22","doi-asserted-by":"publisher","first-page":"316","DOI":"10.5694\/mja2.50758","volume":"213","author":"M Hew","year":"2020","unstructured":"Hew M, McDonald VM, Bardin PG, et al. Cumulative dispensing of high oral corticosteroid doses for treating asthma in Australia. Med J Aust. 2020;213(7):316\u201320.","journal-title":"Med J Aust"},{"issue":"1","key":"2967_CR23","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.jaci.2017.04.009","volume":"141","author":"PW Sullivan","year":"2018","unstructured":"Sullivan PW, Ghushchyan VH, Globe G, Schatz M. Oral corticosteroid exposure and adverse effects in asthmatic patients. J Allergy Clin Immunol. 2018;141(1):110-6.e7.","journal-title":"J Allergy Clin Immunol"},{"key":"2967_CR24","doi-asserted-by":"publisher","first-page":"193","DOI":"10.2147\/JAA.S176026","volume":"11","author":"DB Price","year":"2018","unstructured":"Price DB, Trudo F, Voorham J, et al. Adverse outcomes from initiation of systemic corticosteroids for asthma: long-term observational study. J Asthma Allergy. 2018;11:193\u2013204.","journal-title":"J Asthma Allergy"},{"issue":"4","key":"2967_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.waojou.2023.100760","volume":"16","author":"JF Maspero","year":"2023","unstructured":"Maspero JF, Cruz AA, Beltran CFP, et al. The use of systemic corticosteroids in asthma management in Latin American countries. World Allergy Organ J. 2023;16(4): 100760.","journal-title":"World Allergy Organ J"},{"issue":"8","key":"2967_CR26","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1111\/resp.14533","volume":"28","author":"R Dhar","year":"2023","unstructured":"Dhar R, Rhee CK, Perng D-W, et al. The burden of systemic corticosteroid use in asthma management in Asia. Respirology. 2023;28(8):744\u201357.","journal-title":"Respirology"},{"key":"2967_CR27","doi-asserted-by":"publisher","first-page":"1514","DOI":"10.3389\/fphys.2019.01514","volume":"10","author":"C Pelaia","year":"2019","unstructured":"Pelaia C, Paoletti G, Puggioni F, et al. Interleukin-5 in the pathophysiology of severe asthma. Front Physiol. 2019;10:1514.","journal-title":"Front Physiol"},{"key":"2967_CR28","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/879783","volume":"2015","author":"G Pelaia","year":"2015","unstructured":"Pelaia G, Vatrella A, Busceti MT, et al. Cellular mechanisms underlying eosinophilic and neutrophilic airway inflammation in asthma. Mediators Inflamm. 2015;879783.","journal-title":"Mediators Inflamm"},{"issue":"3","key":"2967_CR29","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1016\/j.chest.2021.04.013","volume":"160","author":"LG Heaney","year":"2021","unstructured":"Heaney LG, Perez de Llano L, Al-Ahmad M, et al. Eosinophilic and noneosinophilic asthma: an expert consensus framework to characterize phenotypes in a global real-life severe asthma cohort. Chest. 2021;160(3):814\u201330.","journal-title":"Chest"},{"key":"2967_CR30","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.3389\/fimmu.2018.02220","volume":"9","author":"K Nakagome","year":"2018","unstructured":"Nakagome K, Nagata M. Involvement and possible role of eosinophils in asthma exacerbation. Front Immunol. 2018;9:2220.","journal-title":"Front Immunol"},{"issue":"10","key":"2967_CR31","first-page":"619","volume":"41","author":"MS Choy","year":"2016","unstructured":"Choy MS, Dixit D, Bridgeman MB. Mepolizumab (Nucala) for severe eosinophilic asthma. P t. 2016;41(10):619\u201322.","journal-title":"P t"},{"key":"2967_CR32","doi-asserted-by":"publisher","first-page":"49","DOI":"10.3389\/fmed.2018.00049","volume":"5","author":"F Roufosse","year":"2018","unstructured":"Roufosse F. Targeting the interleukin-5 pathway for treatment of eosinophilic conditions other than asthma. Front Med (Lausanne). 2018;5:49.","journal-title":"Front Med (Lausanne)"},{"key":"2967_CR33","unstructured":"FDA. Nucala (mepolizumab) for injection, for subcutaneous use. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/125526Orig1s021,761122Orig1s011Corrected_lbl.pdf. Accessed 2 July 2024."},{"key":"2967_CR34","unstructured":"EMA. Nucala (mepolizumab) an overview of nucala and why it is authorised in the EU. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/nucala. Accessed 2 July 2024."},{"issue":"1","key":"2967_CR35","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1164\/rccm.200801-060ST","volume":"180","author":"HK Reddel","year":"2009","unstructured":"Reddel HK, Taylor DR, Bateman ED, et al. An official American Thoracic Society\/European Respiratory Society statement: asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical practice. Am J Respir Crit Care Med. 2009;180(1):59\u201399.","journal-title":"Am J Respir Crit Care Med"},{"issue":"9842","key":"2967_CR36","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1016\/S0140-6736(12)60988-X","volume":"380","author":"ID Pavord","year":"2012","unstructured":"Pavord ID, Korn S, Howarth P, et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet. 2012;380(9842):651\u20139.","journal-title":"Lancet"},{"issue":"13","key":"2967_CR37","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1056\/NEJMoa1403291","volume":"371","author":"EH Bel","year":"2014","unstructured":"Bel EH, Wenzel SE, Thompson PJ, et al. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N Engl J Med. 2014;371(13):1189\u201397.","journal-title":"N Engl J Med"},{"issue":"10","key":"2967_CR38","doi-asserted-by":"publisher","first-page":"2646","DOI":"10.1016\/j.jaip.2022.05.042","volume":"10","author":"C Pilette","year":"2022","unstructured":"Pilette C, Canonica GW, Chaudhuri R, et al. REALITI-A study: real-world oral corticosteroid-sparing effect of mepolizumab in severe asthma. J Allergy Clin Immunol Pract. 2022;10(10):2646\u201356.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"15","key":"2967_CR39","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1007\/s40265-021-01597-9","volume":"81","author":"C Domingo Ribas","year":"2021","unstructured":"Domingo Ribas C, Carrillo D\u00edaz T, Blanco Aparicio M, et al. Real world effectiveness and safety of mepolizumab in a multicentric Spanish cohort of asthma patients stratified by eosinophils: the REDES study. Drugs. 2021;81(15):1763\u201374.","journal-title":"Drugs"},{"issue":"suppl 66","key":"2967_CR40","first-page":"4589","volume":"60","author":"C Caruso","year":"2022","unstructured":"Caruso C, Canonica GW, Patel M, et al. International, prospective study of mepolizumab in severe asthma: REALITI-A at 2yrs. Eur Respir J. 2022;60(suppl 66):4589.","journal-title":"Eur Respir J"},{"issue":"4","key":"2967_CR41","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1016\/j.jaci.2009.06.053","volume":"124","author":"M Schatz","year":"2009","unstructured":"Schatz M, Kosinski M, Yarlas AS, Hanlon J, Watson ME, Jhingran P. The minimally important difference of the Asthma Control Test. J Allergy Clin Immunol. 2009;124(4):719-23.e1.","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"2967_CR42","doi-asserted-by":"publisher","first-page":"21","DOI":"10.2169\/internalmedicine.9339-22","volume":"62","author":"T Hirano","year":"2023","unstructured":"Hirano T, Matsunaga K. Measurement of blood eosinophils in asthma and chronic obstructive pulmonary disease. Intern Med. 2023;62(1):21\u20135.","journal-title":"Intern Med"},{"issue":"5","key":"2967_CR43","doi-asserted-by":"publisher","first-page":"2102583","DOI":"10.1183\/13993003.02583-2021","volume":"60","author":"D Thomas","year":"2022","unstructured":"Thomas D, McDonald VM, Pavord ID, Gibson PG. Asthma remission: what is it and how can it be achieved? Eur Respir J. 2022;60(5):2102583.","journal-title":"Eur Respir J"},{"issue":"6","key":"2967_CR44","doi-asserted-by":"publisher","first-page":"2300819","DOI":"10.1183\/13993003.00819-2023","volume":"62","author":"PJ McDowell","year":"2023","unstructured":"McDowell PJ, McDowell R, Busby J, et al. Clinical remission in severe asthma with biologic therapy: an analysis from the UK Severe Asthma Registry. Eur Respir J. 2023;62(6):2300819.","journal-title":"Eur Respir J"},{"key":"2967_CR45","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202311-2192OC","author":"L Perez-de-Llano","year":"2024","unstructured":"Perez-de-Llano L, Scelo G, Tran TN, et al. Exploring definitions and predictors of severe asthma clinical remission post-biologic in adults. Am J Respir Crit Care Med. 2024. https:\/\/doi.org\/10.1164\/rccm.202311-2192OC.","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"2967_CR46","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.anai.2023.08.021","volume":"132","author":"G Scelo","year":"2024","unstructured":"Scelo G, Torres-Duque CA, Maspero J, et al. Analysis of comorbidities and multimorbidity in adult patients in the International Severe Asthma Registry. Ann Allergy Asthma Immunol. 2024;132(1):42\u201353.","journal-title":"Ann Allergy Asthma Immunol"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-024-02967-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-024-02967-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-024-02967-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,15]],"date-time":"2024-10-15T14:08:40Z","timestamp":1729001320000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-024-02967-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,31]]},"references-count":46,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["2967"],"URL":"https:\/\/doi.org\/10.1007\/s12325-024-02967-x","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,31]]},"assertion":[{"value":"17 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Riyad Omar Al-Lehebi has given lectures at meetings supported by AstraZeneca, Boehringer Ingelheim, GSK and Sanofi, and received advisory board fees from GSK. Mona Al Ahmad received lecture and advisory board honoraria from Sanofi, GSK and AstraZeneca. Venkata Nagarjuna Maturu has given lectures at meetings supported by AstraZeneca, GSK, Novartis, Sun Pharma, Cipla and Lupin, and participated in advisory boards with AstraZeneca and GSK. Alejandra Galeano Mesa has no conflicts of interest to report. Bassam Mahboub is a speaker for AstraZeneca, GSK and Sanofi. Elizabeth Garcia reports having been a speaker for Sanofi, Novartis, and Pfizer and received advisory board fees from GSK, Sanofi and Novartis. Patricia Fernandez reports having been a speaker for AstraZeneca, GSK, Sanofi and Teva, and participated in advisory boards with AstraZeneca, GSK and Sanofi. Claudia Soares, Alejandro Raimondi, Maria Laucho-Contreras, Saeed Noibi and Gur Levy are employed by GSK and hold financial equities in GSK. Gabriela Abreu and Juliana Queiroz are complementary employees of GSK and do not hold financial equities in GSK. Debora dos Santos was a complementary worker of GSK at the time of the study analysis. Debora dos Santos\u2019 current affiliation is a postdoctoral fellowship at University of Brasilia under the Program of Collective Health. Sevim Bavbek has given lectures at meetings supported by AstraZeneca, GSK and Novartis, and reports receipt of advisory board fees from AstraZeneca, GSK and Novartis.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The study protocol was reviewed and approved by the respective institutional review boards and ethics committees of the participating countries and the study was conducted in accordance with the International Conference on Harmonization, Good Pharmacoepidemiology Practice, Good Clinical Practice and all applicable patient privacy requirements and country-specific requirements relevant for an observational study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}